Trial Search Results

Adipose-Derived Stem Cell Injections for Knee Osteoarthritis

This is a non-surgical trial comparing the clinical and functional outcomes of patients with osteoarthritis treated with Intra-articular injection of autologous Adipose-Derived Stem Cells (ADSC) combined with platelet-rich plasma (PRP) versus conventional therapy of Intra-articular injection of corticosteroid.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):

Intervention(s):

  • Procedure: Stem Cell injection
  • Drug: Corticosteroid injection

Phase:

Phase 3

Eligibility


Inclusion Criteria:

   - Age between 35 and 75 years-old

   - Diagnosis of pre-existing osteoarthritis of the joint by Kellgren-Lawrence Grade 2 or
   3.

   - Working understanding of the English language and able to fully understand the
   procedure

   - Capable of providing informed consent

   - Able to complete online, in-person or phone surveys for the purposes of follow-up

   - Capable of understanding pre- and post-procedure care instructions

   - Ambulatory at baseline

   - Previous trial and failure of conservative therapy consisting of a minimum of 6 weeks
   of physical therapy and trial of anti-inflammatory medications if not contraindicated,
   with or without concomitant bracing and/or injections.

Exclusion Criteria:

   - Age < 35 or > 75 years old

   - Radiographs demonstrating either no, little or severe osteoarthritis
   (Kellgren-Lawrence Grade 0, 1 )

   - Prior total or partial joint replacement surgery or a surgery involving cartilage
   regeneration (microfracture, ACI, etc)

   - Previous cortisone and/or Hyaluronic acid intra-articular injection within the last 3
   months

   - Co-morbidity with rheumatologic condition, inflammatory arthritis

   - Currently undergoing immunomodulatory therapy

   - Uncontrolled endocrine disorder

   - BMI >35

   - Current diagnosis of osteomyelitis, human immunodeficiency virus (HIV-1, -2) and/or
   hepatitis C (HCV), infection and poorly controlled diabetes (HgA1C >7.0)

   - Pregnancy or planned pregnancy

   - previous stem cell injection into treatment joint

   - Patient scheduled to undergo any concomitant surgical procedures.

   - Coagulopathy or anticoagulant treatment

   - Chronic pain involving multiple body parts or opioid medication management

Ages Eligible for Study

35 Years - 75 Years

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Jason L Dragoo, MD
Recruiting